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Abstract
AIM: To develop a novel endoscopic severity model of 
intestinal Behcet's disease (BD) and to evaluate its fea-
sibility by comparing it with the actual disease activity 
index for intestinal Behcet's disease (DAIBD).
METHODS: We reviewed the medical records of 167 
intestinal BD patients between March 1986 and April 
2011. We also investigated the endoscopic parameters 
including ulcer locations, distribution, number, depth, 
shape, size and margin to identify independent fac-
tors associated with DAIBD. An endoscopic severity 
model was developed using significant colonoscopic 
variables identified by multivariate regression analysis 
and its correlation with the DAIBD was evaluated. To 
determine factors related to the discrepancy between 
endoscopic severity and clinical activity, clinical char-
acteristics and laboratory markers of the patients were 
analyzed.
RESULTS: A multivariate regression analysis revealed 
that the number of intestinal ulcers (≥ 2, P  = 0.031) 
and volcanoshaped ulcers (P  = 0.001) were predictive 
factors for the DAIBD. An endoscopic severity model (Y) 
was developed based on selected endoscopic variables 
as follows: Y = 47.44 + 9.04 × non-Ileocecal area 
+ 11.85 × ≥ 2 of intestinal ulcers + 5.03 × shallow 
ulcers + 12.76 × deep ulcers + 4.47 × geographic-
shaped ulcers + 26.93 × volcano-shaped ulcers + 8.65 
× ≥ 20 mm of intestinal ulcers. However, endoscopic 
parameters used in the multivariate analysis explained 
only 18.9% of the DAIBD variance. Patients with se-
vere DAIBD scores but with moderately predicted 
disease activity by the endoscopic severity model had 
more symptoms of irritable bowel syndrome (21.4% 
vs  4.9%, P  = 0.026) and a lower rate of corticosteroid 
use (50.0% vs  75.6%, P  = 0.016) than those with se-
vere DAIBD scores and accurately predicted disease by 
the model. 
CONCLUSION: Our study showed that the number of 
intestinal ulcers and volcano-shaped ulcers were pre-
dictive factors for severe DAIBD scores. However, the 
correlation between endoscopic severity and DAIBD (r  
= 0.434) was weak.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Behcet's disease (BD) is a chronic, relapsing, multi-sys-
temic inflammatory disorder characterized by recurrent 
oral and genital ulcers combined with other systemic 
manifestations. The systemic manifestations are due to 
involvement of  many other organs including the skin, 
joints, blood vessels, nervous system, epididymis, and 
gastrointestinal tract[1,2]. In particular, when patients with 
BD have predominant gastrointestinal symptoms and 
show intestinal ulcerations according to objective mea-
sures, the disease is then diagnosed as "intestinal BD"[3,4].
Intestinal BD is generally accepted as a type of  in-
flammatory bowel disease (IBD), a group of  diseases 
that includes ulcerative colitis (UC) and Crohn's dis-
ease (CD). Because IBD has various, fluctuated clinical 
courses with repeated remission and relapse, the disease 
activity index is helpful for disease management and 
therefore has been commonly used in monitoring treat-
ment response. For example, disease activity is usually 
defined according to the Truelove and Witts' criteria[5] 
or the Mayo score system[6] as mild, moderate, or severe 
disease for UC and measured by the Crohn's disease 
activity index (CDAI)[7] or the Harvey-Bradshaw index[8] 
for CD. 
 Endoscopy is by far the best and most widely used 
modality for assessment of  the disease extent and se-
verity of  IBD[9]. A study investigating a cohort of  CD 
patients under long-term treatment with infliximab re-
cently reported that mucosal healing was associated with 
a significantly lower need for abdominal surgery[10]. Fur-
thermore, data from the Active Ulcerative Colitis Trials 
1 and 2[11] have suggested that mucosal healing was as-
sociated with a better outcome in UC, more specifically, 
a decreased risk of  relapse. Therefore, the macroscopic 
mucosal appearance is considered a valuable indicator of  
disease activity. In this regard, colonoscopic activity has 
been assessed using a modified version of  Baron's crite-
ria[12] for UC and the Crohn's disease endoscopic index 
of  severity (CDEIS)[13] for CD.
Although the disease activity index for intestinal 
Behcet's disease (DAIBD), a relatively simple eight-point 
system, was recently introduced[14], there are no specific 
tools for the measurement of  endoscopic severity in in-
testinal BD. There have been several descriptions of  clin-
ical outcomes according to colonoscopic findings[15,16], 
however, endoscopic appearance has never been taken 
into account in evaluating disease activity in intestinal 
BD. Therefore, the aim of  this study was to identify en-
doscopic factors associated with the DAIBD, to develop 
a novel endoscopic severity model of  intestinal BD using 
these factors, and to evaluate the correlations between 
the actual DAIBD and endoscopic severity.
MATERIALS AND METHODS
Patients
We reviewed the medical records of  patients with intesti-
nal BD at Severance Hospital, Yonsei University College 
of  Medicine, Seoul, South Korea, between March 1986 
and April 2011. Patients with a history of  previous colon 
operations were excluded from the study and those diag-
nosed or suspected as having UC, CD, intestinal tubercu-
losis, infectious colitis, or malignancy were not included 
in our study. 
BD was diagnosed according to the criteria from the 
1987 Behcet's Disease Research Committee of  Japan[17] 
and was divided into the following three types: complete, 
incomplete and suspected BD. Intestinal involvement of  
BD was evaluated using colonoscopy for the large bowel 
and terminal ileum involvement and small bowel follow-
through or computed tomography enterography for 
the small bowel involvement in patients with BD who 
had gastrointestinal symptoms. Diagnosis of  intestinal 
BD was made according to the criteria as previously 
described using a modified Delphi process[2,18]. Patients 
were categorized into three groups as definite, probable, 
and suspected on the basis of  colonoscopic findings and 
extraintestinal systemic manifestations. Clinical activity 
of  intestinal BD was judged by the DAIBD composed 
of  the following eight variables: general well-being, fever, 
extraintestinal manifestations, abdominal pain, abdomi-
nal mass, intestinal complications, and number of  liquid 
stools in one week. The DAIBD was classified into qui-
escent (≤ 19), mild (20-39), moderate (40-74), and severe 
disease (≥ 75)[14].
Methods
We collected demographic data including initial gastro-
intestinal symptoms and other extraintestinal manifesta-
tions related to systemic BD at the time of  colonoscopy. 
We also investigated all colonoscopic findings with 
respect to location, distribution, number, depth, shape, 
size, and ulcer margin. Patients with < 5 ulcers that were 
oval in shape, deep, with discrete borders, and located in 
the ileocecal area including the terminal ileum, ileocecal 
valve, and cecum were considered as having typical in-
testinal BD lesions[19]. When the colon was divided into 
five segments (ileocecal area, ascending colon, transverse 
colon, descending colon, and rectosigmoid colon), a lo-
calized type was defined when lesions were restricted to 
only one segment and a diffuse type was defined when 
lesions were scattered in more than two colonic seg-
ments[15]. Furthermore, when two or more ulcers were 
observed, the largest diameter of  the biggest ulcer was 
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used for the measurement of  depth, shape, size and 
margin for analysis. This study was approved by the In-
stitutional Review Board of  Yonsei University College 
of  Medicine and was conducted in accordance with the 
ethical principles of  the Declaration of  Helsinki.
Statistical analysis
Continuous variables are presented as mean ± SD and 
categorical variables as frequency and percentage. An 
endoscopic severity model was constructed using the 
DAIBD as a dependent variable and the following endo-
scopic parameters as explanatory variables: ulcer location, 
distribution, number, depth, shape, size, and margin. To 
identify independent factors associated with disease ac-
tivity for intestinal BD, we selected explanatory items us-
ing univariate analysis (P < 0.05) and also items that were 
recommended to be included by experts, which were 
followed by multiple linear regression analysis. The inde-
pendent variables were evaluated using Student's t-test or 
one-way analysis of  variance, with post hoc tests for con-
firmation of  significance (Tukey's test at α  = 0.05). R2 in 
the regression is used for how much the variance of  the 
DAIBD can be explained by the endoscopic parameters. 
Moreover, relationships between predicted scores and 
the DAIBD were evaluated using Spearman's correlation 
coefficients.
Using an endoscopic severity model, we sought to 
predict actual disease activity for intestinal BD. To evalu-
ate factors associated with any discrepancy between the 
predicted score using an endoscopy severity model and 
the actual DAIBD, we divided patients into four groups 
(quiescent, mild, moderate, and severe groups) according 
to their actual DAIBD cutoff  scores and analyzed clini-
cal characteristics and laboratory markers in each group. 
They were further classified according to their predicted 
DAIBD scores using the endoscopic model. Two of  
the groups of  patients with the actual DAIBD scores 
showed values consistent with the predicted scores 
by the endoscopic model, while the other two groups 
of  patients showed disagreement between the actual 
DAIBD and predicted scores; one with lower predicted 
scores than the actual DAIBD scores and the other with 
higher predicted scores than the actual DAIBD scores. 
Student's t-test was used to compare continuous vari-
ables and chi-squared test was used to compare categori-
cal variables for each group. 
P < 0.05 was considered statistically significant for all 
tests. All statistical analyses were performed using SPSS 
Version 17.0 for Windows (SPSS Inc., Chicago, IL, Unit-
ed States) and/or SAS Version 9.1 (SAS Institute, Gary, 
NC, United States). 
RESULTS
Baseline clinical and colonoscopic characteristics of 
patients with intestinal BD
A total of  243 patients with intestinal BD were recruited 
during the study period, and 72 of  243 patients were 
excluded because they underwent operations such as 
ileocecectomy, right hemicolectomy, or small bowel 
resection before undergoing colonoscopy. One patient 
was excluded after finally being diagnosed with CD af-
ter follow-up colonoscopy, and 3 patients were further 
excluded who were confirmed not to have intestinal BD 
at the end of  the follow-up period. The remaining 167 
patients were included in this study. Their clinical and 
colonoscopic characteristics are summarized in Tables 1 
and 2, respectively. 
The mean age at diagnosis was 38.5 years (range:15-73 
years) for BD and 41.4 years (range: 16-73 years) for in-
testinal BD. Ninety-six patients (57.5%) were female. Ac-
cording to the diagnostic criteria for BD, 3 patients (1.8%) 
had the complete type, 78 (46.7%) had the incomplete 
type, and 53 (31.7%) had the suspected type of  disease. 
Twenty-five patients (15.0%) presented with only typical 
oral ulcers and 8 (4.8%) had only gastrointestinal lesions 
without any extraintestinal manifestations. The chief  
complaints of  patients were diarrhea (85.0%), abdomi-
nal pain (71.8%), and abdominal tenderness (71.2%). At 
the time of  colonoscopy, 5-aminosalicylic acids or sul-
fasalazine were prescribed to almost all the patients with 
intestinal BD (97.6%), azathioprine or 6-mercaptopurine 
to 24 patients (14.4%), colchicine to 80 (47.9%), and 
corticosteroids to 72 (43.1%). 
On colonoscopy, the ileocecal area was the most 
common location for intestinal lesions (156 patients, 
93.4%), with ileal ulcers present in 4 (2.4%). Localized 
intestinal involvement was found in 142 patients (85.0%) 
and 86 (51.5%) had a solitary intestinal ulcer. Regarding 
the depth and shape of  intestinal ulcers, 109 patients 
(65.3%) had deep ulcers and 79 (47.3%) had oval-shaped 
ulcers. Patients with intestinal BD had relatively large ul-
cers; ulcers larger than 20 mm were noted in 82 patients 
(49.1%). The ulcer margins were usually discrete (75 pa-
tients, 44.9%), and 94 patients (56.3%) had typical ulcers. 
With regard to the intestinal BD diagnostic criteria, 69 
(41.3%), 82 (49.1%), and 16 patients (9.6%) were clas-
sified as definite, probable, and suspected types, respec-
tively. 
Endoscopic factors associated with disease activity for 
intestinal BD
Univariate analysis revealed that the depth of  intestinal 
ulcers (F = 5.03, P = 0.008), ulcer shape (F = 13.33, P 
< 0.001), and ulcer size (F = 6.62, P < 0.001) were sig-
nificantly associated with disease activity for intestinal 
BD (Table 3). The mean DAIBD score of  deep ulcers 
was significantly greater than that of  shallow ulcers as 
shown by Tukey's multiple comparison test (P = 0.027) 
and the mean DAIBD score of  volcano-shaped ulcers 
was also greater than that of  oval-shaped or geographic 
ulcers (P < 0.001 and P = 0.001, respectively). The 
mean DAIBD score of  ulcers larger than 20 mm was 
significantly greater than that of  ulcers less than 5 mm 
or ulcers ranging from 10 mm to 20 mm (P = 0.014 and 
P = 0.002, respectively). No difference in the DAIBD 
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score was observed with regard to any other endoscopic 
variables including location, distribution, number, or 
pattern of  ulcer margin.
Significant variables (P < 0.05) found on univari-
ate analysis were included in the multivariate analysis to 
identify independent factors associated with disease ac-
tivity. Location and number of  ulcers that experts have 
recommended as potentially important predictive factors 
were also included in the multivariate analysis. Multivari-
ate regression analysis showed that the number of  intes-
tinal ulcers (≥ 2, P = 0.031) and that of  volcano-shaped 
ulcers (P = 0.001) were independent predictive factors 
for the DAIBD (Table 4). 
 Using the coefficients from the estimated regression 
model (Table 4), we generated an endoscopic sever-
ity model to predict DAIBD scores (Y) based on five 
optimal selected endoscopic variables. The final model 
was as follows: Y = 47.44 + 9.04 × non-ileocecal area 
+ 11.85 × ≥ 2 of  intestinal ulcers + 5.03 × shallow ul-
cers + 12.76 × deep ulcers + 4.47 × geographic-shaped 
ulcers + 26.93 × volcano-shaped ulcers + 8.65 × ≥ 20 
mm of  intestinal ulcers. 
Predictive factors for discrepancies between predicted 
endoscopic score and actual DAIBD
However, the five most predictive endoscopic parameters 
in the multiple linear regression analysis explained only 
18.9% of  the DAIBD variance. Therefore, we attempted 
to find out the reasons for this unexpected discrepancy. 
Using the endoscopic severity model, the predicted 
DAIBD severity distribution was as follows: 108 patients 
(64.7%) had moderate disease activity and 59 (35.3%) had 
severe disease activity (Table 5). Conversely, in this study, 
the actual DAIBD scores demonstrated that disease activ-
ity was quiescent in 2 patients (1.2%), mild in 32 (19.2%), 
moderate in 50 (29.9%), and severe in 83 (49.7%).
Table 1  Baseline clinical characteristics of patients with intes-
tinal Behcet’s disease
Characteristic No. of patient (%)
Age at diagnosis of BD (yr) 38.5 ± 12.2
Age at diagnosis of intestinal BD (yr) 41.4 ± 12.3
Gender (male:female)      71:96 (42.5:57.5)
Systemic symptoms and signs of BD
   Recurrent oral ulcer 159 (95.2)
   Recurrent genital ulcer   78 (46.7)
   Ocular lesion 10 (6.0)
   Skin lesion   82 (49.1)
   Positive pathergy test   4 (2.4)
   Arthritis or arthralgia   66 (39.5)
   Neurologic lesion                 0
   Vascular lesion   2 (1.2)
Clinical subtype of BD
   Complete   3 (1.8)
   Incomplete   78 (46.7)
   Suspected   53 (31.7)
Symptoms and signs of intestinal involvement
   Abdominal pain 120 (71.8)
   Diarrhea 142 (85.0)
   Abdominal mass   4 (2.4)
   Tenderness 119 (71.2)
   Nausea/vomiting   4 (2.4)
   Melena/hematochezia   31 (18.6)
Fistula   4 (2.4)
   Stenosis (intestinal obstruction) 10 (6.0)
   Abscess                 0
   Perforation                 0
Current use of medication
   5-ASA or sulfasalazine 163 (97.6)
   Azathioprine or 6-mercaptopurine   24 (14.4)
   Colchicine   80 (47.9)
   Corticosteroid    72 (43.1)
Patient global assessment 
   Well   63 (37.7)
   Mild   53 (31.7)
   Moderate   45 (26.9)
   Severe   6 (3.6)
DAIBD 74.9 ± 36.1 (5-155)
   Quiescent (≤ 19)   2 (1.2)
   Mild (20-39)   32 (19.2)
   Moderate (40-74)   50 (29.9)
   Severe (≥ 75)   83 (49.7)
BD: Behcet’s disease; DAIBD: Disease activity index for intestinal Behcet’s 
disease; 5-ASA: 5-aminosalicylic acid.
Table 2  Baseline colonoscopic characteristics of patients with 
intestinal Behcet’s disease
Characteristic No. of patient (%)
Location of intestinal lesion   4 (2.4)
   Ileal area 156 (93.4)
   Ileocecal area   25 (15.0)
   Ascending colon   18 (10.8)
   Other colonic segment
Distribution of intestinal lesion
   Localized involvement 142 (85.0)
   Diffuse involvement   25 (15.0)
Number of intestinal ulcer
   Solitary   86 (51.5)
   2-5   53 (31.7)
   ≥ 5   28 (16.8)
Depth of intestinal ulcer
   Aphthous 12 (7.2)
   Shallow   46 (27.5)
   Deep 109 (65.3)
Shape of intestinal ulcer
   Oval   79 (47.3)
   Geographic   52 (31.1)
   Volcano   36 (21.6)
Size of intestinal ulcer (mm)
   < 5 11 (6.6)
   5-10   29 (17.4)
   10-20   45 (26.9)
   ≥ 20   82 (49.1)
Margin of intestinal ulcer
   Discrete   75 (44.9)
   Elevation 13 (7.8)
   Nodular elevation   32 (19.2)
   Marginal erythema   47 (28.1)
Type of intestinal ulcer
   Typical type   94 (56.3)
   Atypical type   73 (43.7)
Diagnostic criteria of intestinal BD
   Definite   69 (41.3)
   Probable   82 (49.1)
   Suspected 16 (9.6)
BD: Behcet’s disease.
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To find out which predictive factors are causing 
discrepancies between the predicted endoscopic scores 
and the actual DAIBD scores, we first analyzed 83 pa-
tients with severe actual DAIBD scores. Among the 83 
patients, 42 (50.6%) had moderate and 41 (49.4%) had 
severe predicted disease activity based on the endoscopic 
severity model. Moderately predicted group had more 
irritable bowel syndrome symptoms (21.4% vs 4.9%, P = 
0.026) and a lower rate of  corticosteroid use (50.0% vs 
75.6%, P = 0.016) than severely predicted group. How-
ever, infection rates (16.7% vs 12.2%, P = 0.562) and 
rates of  systemic BD presentation (57.1% vs 46.3%, P = 
0.325) were not significantly different between the two 
groups.
Among the remaining 84 patients with mild or mod-
erate DAIBD, 37 patients (44.0%) showed consistent 
results between the actual DAIBD and their predicted 
scores, while 47 (56.0%) showed inconsistent results. 
Clinical or laboratory variables including rate of  corti-
costeroid use (25.5% vs 21.6%, P = 0.676), erythrocyte 
sedimentation rate (ESR) (39.15 ± 27.66 mm/h vs 33.74 
± 27.98 mm/h, P = 0.421), or C-reactive protein (CRP) 
level  (7.11 ± 18.33 mg/L vs 2.81 ± 3.99 mg/L, P = 0.162) 
were not significantly different between the two groups.
DISCUSSION
To the best of  our knowledge, there have been no stud-
ies concerning endoscopic factors associated with disease 
activity for intestinal BD. Moreover, there is currently 
no available endoscopic severity model for intestinal 
BD. To date, the management of  intestinal BD and the 
assessment of  its response to treatment depend heavily 
on expert opinions. Although recently, the DAIBD was 
proposed to objectively evaluate disease activity, which 
would be useful to physicians in clinical practice[14], en-
doscopy has rarely been investigated as a predictor of  
disease activity in intestinal BD. Accordingly, we aimed 
to identify endoscopic factors related to disease activity 
of  intestinal BD, to develop a novel scoring model for 
predicting a severe course of  disease, and to clarify the 
correlation between the DAIBD and endoscopic severity.
In the present study, we first sought to identify the 
endoscopic factors associated with disease activity for 
intestinal BD. On univariate analysis, the significant en-
doscopic predictors of  disease activity were depth of  
intestinal ulcers, ulcer shape and ulcer size. Multivariate 
analysis revealed that the number of  intestinal ulcers and 
volcano-shaped ulcers were independent predictors of  
the DAIBD. These results were consistent with those 
of  several prior studies. A Korean study[15] reported that 
volcano-shaped ulcers responded least to medical treat-
Table 3  Univariate analysis of endoscopic factors associated 
with the disease activity index for intestinal Behcet’s disease 
Endoscopic factor DAIBD (mean ± SD) F/t  value P  value
Location 0.48 0.632
   Ileocecal area 74.58 ± 36.74
   Other 80.00 ± 26.08
Distribution
   Localized 73.98 ± 35.22     -0.82 0.414
   Diffuse 80.40 ± 41.10
Number of intestinal ulcer 0.39 0.679
   Solitary 72.67 ± 30.92
   2- 5 76.51 ± 41.75
   ≥ 5 78.93 ± 40.08
Depth of intestinal ulcer 5.03 0.008
   Aphthous 57.08 ± 37.02
   Shallow 65.00 ± 30.09
   Deep 81.10 ± 37.01
Shape of intestinal ulcer 13.33 < 0.001
   Oval 65.13 ± 37.79
   Geographic 72.60 ± 28.40
   Volcano 99.86 ± 30.95
Size of intestinal ulcer (mm) 6.62 < 0.001
   < 5 52.73 ± 35.45
   5-10 69.48 ± 36.38
   10-20 63.00 ± 33.02
   ≥ 20 86.40 ± 34.29
Margin of intestinal ulcer 1.95 0.124
   Discrete 80.47 ± 37.70
   Elevation 56.54 ± 33.63
   Nodular elevation 75.47 ± 29.93
   Marginal erythema 70.85 ± 36.81
DAIBD: Disease activity index for intestinal Behcet’s disease.
Table 4  Multivariate analysis of endoscopic factors associated 
with the disease activity index for intestinal Behcet’s disease 
Endoscopic factor β coefficient P  value
Intercept 47.44
Location
   Ileocecal area                       0
   Other  9.04 0.389
Number of intestinal ulcer 
   Solitary                       0
   ≥ 2 11.85 0.031
Depth of intestinal ulcer
   Aphthous                       0
   Shallow  5.03 0.651
   Deep 12.76 0.261
Shape of intestinal ulcer
   Oval                       0
   Geographic  4.47 0.495
   Volcano 26.93 0.001
Size of intestinal ulcer (mm)
   < 20                       0
   ≥ 20  8.65 0.225
Actual DAIBD Predicted DAIBD by an endoscopic model Total
Quiescent 
(≤19)
Mild 
(20-39)
Moderate 
(40-74)
Severe 
(≥ 75)
Quiescent (≤ 19) 0 0   1  1   2
Mild (20-39) 0 0 28  4 32
Moderate (40-74) 0 0 37 13 50
Severe (≥ 75) 0 0 42 41 83
Total 0 0       108 59  167
Table 5  Predicted and actual disease activity index for intesti-
nal Behcet’s disease scores in intestinal Behcet’s disease patients
DAIBD: Disease activity index for intestinal Behcet’s disease.
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ment, required surgery more frequently, and showed 
more frequent recurrences than geographic and aph-
thous-shaped ulcers. Another Korean study[16] revealed 
that individuals with deep ulcers and ulcers larger than 
20 mm had an increased rate of  steroid use and more 
frequent intestinal surgery. Moreover, a recent study by 
Jung et al[20] suggested that those with volcano-shaped 
ulcers demonstrated a less favorable response to surgi-
cal treatment, had more frequent recurrences, and more 
frequently required reoperation. In addition to volcano-
shaped, deep, and larger than 20 mm ulcers, this study 
showed for the first time that having two or more intes-
tinal ulcers was related to an increased disease severity 
when compared to solitary ulcers. Although there have 
been no reports regarding the correlations between the 
number of  ulcers and disease activity in IBD, our re-
sults can be explained by the fact that an increase in the 
extent of  mucosal involvement reflects the multiplicity 
of  ulcers because patients with extensive and multiple 
ulcers are less likely to respond to local or systemic treat-
ments. In systemic BD, the number, frequency, and heal-
ing time of  oral ulcers and pain have been used to evalu-
ate disease activity in clinical practice and studies[21]. In 
addition, in our study, ulcers in the ileocecal area showed 
a lower DAIBD score than ulcers in other location. A 
recent study on free bowel perforation in intestinal BD 
patients[22] reported that small bowel perforation was 
observed in 21.2%. Ileal ulcers might be at higher risk of  
complications such as perforation, which could be there-
fore related to severe disease activity. Further studies are 
required to validate whether the number of  intestinal 
ulcers and ulcer location are truly associated with disease 
activity in intestinal BD.
Based on the predictive endoscopic factors for dis-
ease activity identified on multivariate analysis, we sought 
to develop an endoscopic severity model for intestinal 
BD. In multivariate analysis, besides the factors found to 
be significantly associated with the DAIBD in univariate 
analysis, potential factors that could achieve the opti-
mized R2 were also included, reflecting experts' sugges-
tions. Initially, we hypothesized that endoscopic severity 
would have a highly significant correlation with clinical 
activity. However, the correlation between endoscopic 
severity and the DAIBD (r = 0.434) was unexpectedly 
found to be substantially weak. These results suggest 
that endoscopic severity might not correlate with clini-
cal disease activity; thus, we cannot precisely judge a 
patient's condition using only the clinical activity index. 
Another potential reason for the lack of  correlation may 
be that improvement in endoscopic lesions appeared lat-
er than the patient's clinical status. Although there have 
been no reports on correlations between endoscopic 
severity and disease activity in intestinal BD, many previ-
ous studies have described a poor association between 
endoscopic severity and clinical activity in IBD. In CD, 
the Groupe d'Etudes Therapeutiques des Affections In-
flammatoires Digestives have shown that endoscopic se-
verity patterns assessed by the CDEIS correlated poorly 
(r = 0.32) with clinical activity measured by the CDAI[23]. 
Daperno et al[24] indicated that the correlation of  the sim-
ple endoscopic score for CD with CDAI (r = 0.39) was 
better than for the CDEIS, but still far from optimal. In 
contrast, Allez et al[25] observed that patients with CD ex-
hibiting deep and extensive ulcerations on colonoscopy 
have a more aggressive clinical course with an increased 
rate of  penetrating complications and increased likeli-
hood of  surgery. In UC, Carbonnel et al[26] demonstrated 
that extensive and deep ulcerations observed on colo-
noscopy were associated with an increased risk of  colec-
tomy, and another study by Daperno et al[27] reported that 
severe endoscopic lesions were significantly more fre-
quent in non-responders to medical treatment compared 
with responders. These findings suggest that clinical dis-
ease activities might not highly correlate with concrete 
progress of  patients. Endoscopic activity indexes could 
complement this drawback of  clinical indices of  IBD 
including intestinal BD. Further large-scale studies are 
needed to conclude whether endoscopic severity is supe-
rior to clinical disease activity in intestinal BD in terms 
of  reflecting exactly the patient's current condition and 
predicting prognosis.
Because the correlation between endoscopic severity 
and the DAIBD was weak, recognizing reasons for the 
disagreement would be useful for clinicians in practice. 
To determine possible explanatory factors for the dis-
crepancy between endoscopic severity and clinical activ-
ity, we considered laboratory results as well as clinical 
findings. These unexpected results might be explained 
that many systemic manifestations of  the inflamma-
tory process that result in the appearance of  symptoms, 
but are not necessarily reflected in the mucosal lesions. 
Patients with systemic BD symptoms including oral 
and genital ulcers, eye and skin lesions, or arthralgia or 
concomitant infections may present with higher DAIBD 
scores than the predicted scores. Moreover, patients 
with predominant irritable bowel syndrome symptoms 
might present with higher clinical activity scores because 
symptoms of  irritable bowel syndrome include nonspe-
cific abdominal pain or discomfort and changes in stool 
frequency and appearance with the onset of  symptoms, 
which might mimic IBD symptoms[28]. In the present 
study, patients with higher DAIBD scores than predicted 
scores had more irritable bowel syndrome symptoms 
and a lower rate of  corticosteroid use. It is possible that 
clinical symptoms improve more quickly with the use of  
corticosteroids.
Moreover, in a group of  patients with a higher endo-
scopic severity than actual clinical activity, we anticipated 
that serum biomarkers such as CRP and ESR would 
explain the discrepancy because the utility of  laboratory 
markers for assessment of  IBD activity, risk of  complica-
tions, prediction of  relapse and for monitoring the ef-
fect of  therapy have been investigated. Consigny et al[29] 
reported that CRP levels (> 20 mg/dL) and ESR (> 15 
mm/h) were predictive of  relapse in CD, and Travis et al[30] 
revealed that elevated CRP (> 45 mg/L) could predict an 
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increased risk of  colectomy in severe UC. Although many 
studies in the past few decades have noted that CRP and 
ESR are associated with systemic BD activity[31,32], the role 
of  CRP and ESR in intestinal BD is still unknown. In the 
current study, the CRP and ESR levels were numerically 
higher in the severe predicted DAIBD group without any 
statistical difference. A recent study by Jung et al[33] also 
demonstrated that CRP or ESR levels were not highly 
correlated with disease activity in intestinal BD patients. 
Further studies are needed to evaluate the precise role of  
laboratory markers in intestinal BD.
The main strength of  our study is that this is the first 
study to consider the use of  endoscopy as a measure-
ment tool of  disease status in intestinal BD. However, 
because we retrospectively analyzed clinical and colono-
scopic characteristics, our results might have been affect-
ed by the limitations of  its retrospective design. In addi-
tion, the correlations between the predicted endoscopic 
severity model and the disease activity of  intestinal BD 
were far below the expected values. Further studies to 
predict the clinical outcomes more accurately by taking 
into account endoscopic factors and the DAIBD togeth-
er are required to verify our results.
In conclusion, we evaluated endoscopic factors re-
lated to disease activity of  intestinal BD and the cor-
relations between clinical activity and endoscopic sever-
ity. Our findings indicate that clinicians should closely 
observe patients with two or more intestinal ulcers and 
those with volcano-shaped ulcers and that these endo-
scopic findings could help clinicians make decisions re-
garding medical strategies for the treatment of  intestinal 
BD. Finally, the understanding of  discrepancy between 
actual and predicted DAIBD by the endoscopic severity 
model could be helpful in making an appropriate deci-
sion regarding medical strategies.
COMMENTS
Background
Because inflammatory bowel disease (IBD) has various, fluctuated clinical 
courses with repeated remission and relapse, the disease activity index is help-
ful for disease management. Moreover, recent studies suggested that mucosal 
healing was associated with a better outcome. Therefore, the macroscopic mu-
cosal appearance is also considered a valuable indicator of disease activity. In 
this regard, disease activity index including endoscopic severity has been used 
in ulcerative colitis and Crohn's disease (CD). 
Research frontiers
A study investigating a cohort of CD patients under long-term treatment with 
infliximab recently reported that mucosal healing was associated with a signifi-
cantly lower need for abdominal surgery and data from the Active Ulcerative 
Colitis Trials 1 and 2 have suggested that mucosal healing was associated with 
a decreased risk of relapse. Moreover, because endoscopy could provide a 
direct assessment of the disease extent and severity, endoscopic severity has 
been estimated in IBD. However, although the disease activity index for intes-
tinal Behcet's disease (DAIBD) was recently introduced, there are no specific 
tools for the measurement of endoscopic severity in intestinal Behcet's disease 
(BD). 
Innovations and breakthroughs
This is the first study to consider the use of endoscopy as a measurement tool 
of disease status in intestinal BD. Their study demonstrated that the number of 
intestinal ulcers and volcano-shaped ulcers were predictive factors for severe 
DAIBD scores. However, the correlation between endoscopic severity and 
DAIBD (r = 0.434) was weak. Patients with severe DAIBD scores but with mod-
erately predicted disease activity by the endoscopic severity model had more 
symptoms of irritable bowel syndrome and a lower rate of corticosteroid use 
than those with severe DAIBD scores and accurately predicted disease by the 
model.
Applications
This study suggests that clinicians should closely observe patients with two 
or more intestinal ulcers and those with volcano-shaped ulcers and that these 
endoscopic findings could help clinicians make decisions regarding medical 
strategies for the treatment of intestinal BD. Furthermore, the understanding of 
discrepancy between actual and predicted DAIBD by the endoscopic severity 
model could be helpful in making an appropriate decision regarding medical 
strategies.
Terminology
BD is a chronic, relapsing, multi-systemic inflammatory disorder and intestinal 
BD is diagnosed when patients with BD have predominant gastrointestinal 
symptoms and show intestinal ulcerations according to objective measures.
Peer review
In the present study, the authors showed that the number of intestinal ulcers 
and volcano-shaped ulcers were predictive factors for severe DAIBD scores, 
and that the correlation between endoscopic severity and DAIBD (r = 0.434) 
was weak. This study was well-investigated and will give us interesting informa-
tion about the clinical indices of intestinal Behcet's disease.
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